CY1113263T1 - Πολυμορφο τετομιλαστης - Google Patents
Πολυμορφο τετομιλαστηςInfo
- Publication number
- CY1113263T1 CY1113263T1 CY20121100996T CY121100996T CY1113263T1 CY 1113263 T1 CY1113263 T1 CY 1113263T1 CY 20121100996 T CY20121100996 T CY 20121100996T CY 121100996 T CY121100996 T CY 121100996T CY 1113263 T1 CY1113263 T1 CY 1113263T1
- Authority
- CY
- Cyprus
- Prior art keywords
- crystal
- ray powder
- powder diffraction
- diffraction spectrum
- crystals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει κρύσταλλο τετομιλάστης που παράγεται εύκολα βιομηχανικά σε μεγάλο όγκο. (1) κρύσταλλος ένυδρης τετομιλάστης, που έχει φάσμα περίθλασης σκόνης ακτίνων-Χ που έχει χαρακτηριστικές κορυφές σε 2θ = 10,6°, 12,9°, 21,1°, 22,3° και 25,0°, (2) κρύσταλλος ένυδρης τετομιλάστης τύπου C που έχει φάσμα περίθλασης σκόνης ακτίνων-Χ που έχει χαρακτηριστικές κορυφές σε 2θ = 4,2°, 8,2°, 12,0°, 16,4°, 24,7° και 25,9°, (3) κρύσταλλος διαλυτώματος ακετονιτριλίου τετομιλάστης, που έχει φάσμα περίθλασης σκόνης ακτίνων-Χ που έχει χαρακτηριστικές κορυφές σε 2θ = 3,6°, 7,1°, 10,6°, 14,2° και 24,8°. Αυτοί οι κρύσταλλοι είναι σταθεροί έναντι της θερμότητας και της υγρασίας και επίσης είναι εξαιρετικοί όσον αφορά στην ιδιότητα αποσάθρωσης και την ιδιότητα διαλυτοποίησης των δισκίων. Συνεπώς, αυτοί οι κρύσταλλοι κατά προτίμηση χρησιμοποιούνται ως φαρμακευτικές συνθέσεις.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006075307 | 2006-03-17 | ||
EP10160007A EP2206711B1 (en) | 2006-03-17 | 2007-03-15 | Tetomilast polymorph |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113263T1 true CY1113263T1 (el) | 2016-04-13 |
Family
ID=38069222
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100965T CY1111046T1 (el) | 2006-03-17 | 2010-10-25 | Πολυμορφα τετομιλαστης |
CY20121100994T CY1113262T1 (el) | 2006-03-17 | 2012-10-23 | Πολυμορφα τετομιλαστης |
CY20121100996T CY1113263T1 (el) | 2006-03-17 | 2012-10-23 | Πολυμορφο τετομιλαστης |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100965T CY1111046T1 (el) | 2006-03-17 | 2010-10-25 | Πολυμορφα τετομιλαστης |
CY20121100994T CY1113262T1 (el) | 2006-03-17 | 2012-10-23 | Πολυμορφα τετομιλαστης |
Country Status (27)
Country | Link |
---|---|
US (4) | US8501949B2 (el) |
EP (4) | EP1999128B1 (el) |
JP (2) | JP4182363B2 (el) |
KR (6) | KR101118943B1 (el) |
CN (4) | CN101365697B (el) |
AR (1) | AR059911A1 (el) |
AT (1) | ATE476433T1 (el) |
AU (1) | AU2007239906B2 (el) |
BR (1) | BRPI0706224A2 (el) |
CA (4) | CA2725810C (el) |
CY (3) | CY1111046T1 (el) |
DE (1) | DE602007008212D1 (el) |
DK (3) | DK2311832T3 (el) |
ES (3) | ES2390926T3 (el) |
HK (3) | HK1124062A1 (el) |
IL (4) | IL192237A (el) |
MY (2) | MY143808A (el) |
NO (1) | NO20083000L (el) |
PH (1) | PH12015502374A1 (el) |
PL (3) | PL1999128T3 (el) |
PT (3) | PT2311832E (el) |
RU (2) | RU2408597C2 (el) |
SG (4) | SG172707A1 (el) |
SI (3) | SI2311832T1 (el) |
TW (1) | TWI394753B (el) |
WO (1) | WO2007119496A1 (el) |
ZA (2) | ZA200805235B (el) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11186605B2 (en) | 2016-10-06 | 2021-11-30 | Kyowa Hakko Bio Co., Ltd. | Crystal of cytidine diphosphate choline and production method thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3282731B2 (ja) * | 1990-06-15 | 2002-05-20 | メルク エンド カムパニー インコーポレーテッド | 結晶の構造および大きさを改良する結晶化方法 |
DE69132944T2 (de) | 1990-11-30 | 2002-11-21 | Otsuka Pharma Co Ltd | Azolederivate als Inhibitor von Superoxide-Radikalen |
MY128323A (en) * | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
JP4300373B2 (ja) | 1996-09-30 | 2009-07-22 | 大塚製薬株式会社 | サイトカイン産生抑制剤及び接着抑制剤 |
US6221153B1 (en) * | 1998-06-09 | 2001-04-24 | Trevor Percival Castor | Method for producing large crystals of complex molecules |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
GB9922963D0 (en) * | 1999-09-28 | 1999-12-01 | Pfizer Ltd | Polymorphic salt |
JP4336913B2 (ja) | 1999-02-12 | 2009-09-30 | 大塚製薬株式会社 | アミド誘導体の製造方法 |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
WO2003009844A1 (en) * | 2001-07-24 | 2003-02-06 | Otsuka Pharmaceutical Co., Ltd. | Use of thiazole deirvatives for the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease |
JP3713577B2 (ja) | 2001-07-24 | 2005-11-09 | 大塚製薬株式会社 | 慢性閉塞性肺疾患治療薬 |
AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
EP1613598B1 (en) * | 2003-12-16 | 2011-10-19 | Teva Pharmaceutical Industries, Ltd. | Methods of preparing aripiprazole crystalline forms |
-
2007
- 2007-03-14 TW TW096108801A patent/TWI394753B/zh not_active IP Right Cessation
- 2007-03-15 DK DK11152502.8T patent/DK2311832T3/da active
- 2007-03-15 CA CA2725810A patent/CA2725810C/en not_active Expired - Fee Related
- 2007-03-15 PL PL07739373T patent/PL1999128T3/pl unknown
- 2007-03-15 SI SI200731066T patent/SI2311832T1/sl unknown
- 2007-03-15 DK DK07739373.4T patent/DK1999128T3/da active
- 2007-03-15 US US12/086,587 patent/US8501949B2/en not_active Expired - Fee Related
- 2007-03-15 ZA ZA200805235A patent/ZA200805235B/xx unknown
- 2007-03-15 KR KR1020107025457A patent/KR101118943B1/ko not_active IP Right Cessation
- 2007-03-15 DK DK10160007.0T patent/DK2206711T3/da active
- 2007-03-15 CA CA2634100A patent/CA2634100C/en not_active Expired - Fee Related
- 2007-03-15 ES ES10160007T patent/ES2390926T3/es active Active
- 2007-03-15 MY MYPI20082153A patent/MY143808A/en unknown
- 2007-03-15 WO PCT/JP2007/055931 patent/WO2007119496A1/en active Application Filing
- 2007-03-15 KR KR1020117016944A patent/KR101168630B1/ko not_active IP Right Cessation
- 2007-03-15 PL PL10160007T patent/PL2206711T3/pl unknown
- 2007-03-15 DE DE602007008212T patent/DE602007008212D1/de active Active
- 2007-03-15 KR KR1020087016527A patent/KR101083611B1/ko not_active IP Right Cessation
- 2007-03-15 KR KR1020117028259A patent/KR101252994B1/ko not_active IP Right Cessation
- 2007-03-15 SI SI200730386T patent/SI1999128T1/sl unknown
- 2007-03-15 CN CN2007800020022A patent/CN101365697B/zh not_active Expired - Fee Related
- 2007-03-15 SI SI200731065T patent/SI2206711T1/sl unknown
- 2007-03-15 ES ES07739373T patent/ES2348630T3/es active Active
- 2007-03-15 KR KR20127033350A patent/KR101482374B1/ko not_active IP Right Cessation
- 2007-03-15 AT AT07739373T patent/ATE476433T1/de active
- 2007-03-15 BR BRPI0706224-9A patent/BRPI0706224A2/pt not_active IP Right Cessation
- 2007-03-15 CN CN201110065650.0A patent/CN102174044B/zh not_active Expired - Fee Related
- 2007-03-15 EP EP07739373A patent/EP1999128B1/en not_active Not-in-force
- 2007-03-15 PT PT11152502T patent/PT2311832E/pt unknown
- 2007-03-15 SG SG2011043304A patent/SG172707A1/en unknown
- 2007-03-15 AU AU2007239906A patent/AU2007239906B2/en not_active Ceased
- 2007-03-15 EP EP11152502A patent/EP2311832B1/en not_active Not-in-force
- 2007-03-15 RU RU2008127324/04A patent/RU2408597C2/ru not_active IP Right Cessation
- 2007-03-15 PT PT10160007T patent/PT2206711E/pt unknown
- 2007-03-15 EP EP11152503A patent/EP2311833A1/en not_active Withdrawn
- 2007-03-15 SG SG2011043312A patent/SG172708A1/en unknown
- 2007-03-15 RU RU2009147223/04A patent/RU2441002C2/ru not_active IP Right Cessation
- 2007-03-15 CN CN2011100656661A patent/CN102174045A/zh active Pending
- 2007-03-15 CA CA2725698A patent/CA2725698C/en not_active Expired - Fee Related
- 2007-03-15 PL PL11152502T patent/PL2311832T3/pl unknown
- 2007-03-15 ES ES11152502T patent/ES2390957T3/es active Active
- 2007-03-15 CN CN2011100656708A patent/CN102174046B/zh not_active Expired - Fee Related
- 2007-03-15 EP EP10160007A patent/EP2206711B1/en not_active Not-in-force
- 2007-03-15 PT PT07739373T patent/PT1999128E/pt unknown
- 2007-03-15 SG SG2011043296A patent/SG172706A1/en unknown
- 2007-03-15 KR KR1020117028260A patent/KR20110136902A/ko not_active Application Discontinuation
- 2007-03-15 SG SG10201408225VA patent/SG10201408225VA/en unknown
- 2007-03-15 MY MYPI20114235 patent/MY151343A/en unknown
- 2007-03-15 CA CA2725649A patent/CA2725649C/en not_active Expired - Fee Related
- 2007-03-16 AR ARP070101070A patent/AR059911A1/es unknown
- 2007-03-19 JP JP2007069799A patent/JP4182363B2/ja not_active Expired - Fee Related
-
2008
- 2008-06-16 IL IL192237A patent/IL192237A/en unknown
- 2008-07-03 JP JP2008174664A patent/JP5197196B2/ja not_active Expired - Fee Related
- 2008-07-07 NO NO20083000A patent/NO20083000L/no not_active Application Discontinuation
-
2009
- 2009-04-30 HK HK09104006.5A patent/HK1124062A1/xx not_active IP Right Cessation
- 2009-04-30 HK HK11112851.0A patent/HK1159080A1/xx not_active IP Right Cessation
- 2009-04-30 HK HK11112850.1A patent/HK1159079A1/xx not_active IP Right Cessation
-
2010
- 2010-03-09 ZA ZA2010/01687A patent/ZA201001687B/en unknown
- 2010-10-25 CY CY20101100965T patent/CY1111046T1/el unknown
-
2011
- 2011-07-21 IL IL214253A patent/IL214253A/en not_active IP Right Cessation
- 2011-07-21 IL IL214254A patent/IL214254A0/en unknown
- 2011-07-21 IL IL214252A patent/IL214252A0/en unknown
-
2012
- 2012-10-23 CY CY20121100994T patent/CY1113262T1/el unknown
- 2012-10-23 CY CY20121100996T patent/CY1113263T1/el unknown
-
2013
- 2013-03-04 US US13/784,652 patent/US8993601B2/en not_active Expired - Fee Related
- 2013-12-31 US US14/145,260 patent/US9145404B2/en not_active Expired - Fee Related
-
2015
- 2015-08-19 US US14/830,625 patent/US20150352095A1/en not_active Abandoned
- 2015-10-13 PH PH12015502374A patent/PH12015502374A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119669T1 (el) | Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης | |
CY1118498T1 (el) | Παραγωγα πυριδαζινονης | |
CY1111294T1 (el) | Συνθεση αμιδιων ακυλαμινοαλκενυλενιου χρησιμων ως ανταγωνιστων της ουσιας ρ | |
CY1107426T1 (el) | Νεα παραγωγα φθοριογλυκοσιδιων απο πυραζολες, φαρμακευτικα προϊοντα που περιεχουν τις εν λογω ενωσεις και η χρηση αυτων | |
DE602004005033D1 (de) | Benzamidinhibitoren des p2x7-rezeptors | |
ECSP055884A (es) | 3-(3,5 -dioxo-4, 5-dihidro-3h-{1,2,4}triazin-2-il)derivados de benzamidicos como inhibidores del receptor p2x7 para enfermedades inflamatorias | |
CY1115163T1 (el) | Σπειροετεροκυκλικες ν-οξυπιπεριδινες ως ζιζανιοκτονα | |
EA200601274A1 (ru) | Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
SE0102299D0 (sv) | Compounds | |
CY1112222T1 (el) | Ημιενυδρο μεθανοσουλφονικο αλας 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1-μεθυλο-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλο-αμινο]-προπιονικου αιθυλεστερα και η χρηση αυτου ως φαρμακευτικο μεσο | |
MX2007007845A (es) | Sulfonilpirrolidinas, metodo para producir las mismas y su uso como medicamento. | |
CY1113767T1 (el) | Παραγωγα πυριδινης χρησιμα ως ενεργοποιητες γλυκοκινασης | |
MX2010003155A (es) | Derivados de ciclopropil aril amida y uso de los mismos. | |
MX2009009774A (es) | Derivados de quinolina como fungicidas. | |
MX2010003156A (es) | Derivados de aril amida substituida con tetrazol y usos de los mismos. | |
ATE523507T1 (de) | Piperidin-gpcr-agonisten | |
CY1106881T1 (el) | (3-οξο-3,4-διυδρο-κινοξαλιν-2-υλο-αμινο) - βενζαμιδικα παραγωγα και σχετικες ενωσεις ως αναστολεις της φωσφορυλασης γλυκογονου για την αντιμετωπιση του διαβητη και της παχυσαρκιας. | |
MX2007011695A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
HRP20080529T3 (en) | Amide prodrug of gemcitabine, compositions and use thereof | |
CY1110034T1 (el) | Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν | |
BRPI0812222A2 (pt) | Compostos ciclobutenodiona substituídos anti-inflamatórios. | |
TW200722424A (en) | Substituted piperidines | |
NO20092102L (no) | Krystallinformer av aliskiren hemifumarat | |
MX2007011698A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
ATE530176T1 (de) | Verwendung von kaffeesäure und ihren derivaten gegen krebs |